Publicaciones


Luisa L. Rocha - Pharmacoresistance in Epilepsy

 

 

30 de Agosto de 2023

 

Invitamos a leer el artículo: “Pharmacoresistance in Epilepsy”, en la que colaboró la Doctora Luisa L. Rocha, Investigadora de Cinvestav Sede Sur

 

Autores: Luisa L. Rocha, Alberto Lazarowski, Esper A. Cavalheiro Editors

 

Felicitamos al estudiantado y profesorado que contribuyeron en esta investigación por su arduo trabajo.

 

Abstract: Although more than 30 anti-seizure medications are available on the market, epilepsy remains pharmaco-resistant in 30% of patients with focal epilepsy and approximately 10–15% of patients with idiopathic/genetic generalized epilepsy as well. The treatment of these complex patients needs a structured multidisciplinary approach to address the biological, social, and psychological implications. The current chapter is a general overview of epilepsy as a stigma, health, and financial problem and initiatives to change the conditions of patients with epilepsy. Special attention is focused on the effects of pharmacoresistant epilepsy.

 

Keywords: Epilepsy, Pharmacoresistance, Epidemiology, Stigma, Antiseizure medications, International League against Epilepsy, World Health Organization

Print
CONTÁCTENOS

Logo Cinvestav

Calzada de los Tenorios No. 235,
Col. Granjas Coapa, Tlalpan,
Ciudad de México, C.P. 14330

Tel. +52 55 5483 2800

Cinvestav © 2024
22/03/2023 03:27:55 p. m.